- CBD
market projected to grow to $2.1 billion by 2020
- Large
Asian-American market receptive to traditional Chinese medicine and
nutraceuticals
- Cannabis
Strategic Ventures combines brand experience with niche knowledge
Cannabis Strategic Ventures, Inc. (OTC: NUGS) is out to take
a slice of the billion-dollar Asian Nutraceutical pie. The company recently cut
a deal to acquire the Fitamins CBD brand (http://ibn.fm/JzrDg). Under the terms of the agreement,
Fitamins will be distributing its vitamin and hemp-derived CBD formulations
through a network of more than 600 wholesalers that serve the Asian-American
market. Guided by a team that has developed two successful ventures, Cannabis
Strategic Ventures will leverage its knowledge of this underserved market to
provide value to both customers and shareholders.
As large as the Asian-American market is, it is often
overlooked because many marketers are daunted by the communication challenges
involved. Cannabis Strategic Ventures, on the other hand, is comfortable and
familiar with the demographic. The company is led by Simon Yu, BBA, MBA, who
holds the position of CEO. He is supported by Chris Young, who recently joined
Cannabis Strategic Ventures as a board member (http://ibn.fm/J1rdK).
Young is the founder of Pure Applied Sciences, Inc. (PAS),
which is now a subsidiary of Cannabis Strategic Ventures. He holds a JD from
Southwestern Law and an MBA from the University of Southern California, and he
has already built two successful ventures. First, he founded a women’s fashion
brand, which was sold two years later. Second, he co-founded Coordinates
Collection, a luxury jewelry brand that’s marketed to over 500 stores in 10
countries. After his second successful exit, Young moved on to become a
strategy and branding consultant, developing consumer packaged goods (CPG)
products for celebrity-led brands.
The Asian-American nutraceutical market appears to have a
great deal of potential because of its immensity and historical
characteristics. The Chinese segment of this large demographic numbered about
five million in 2015, according to the well-respected Pew Research
Center (http://ibn.fm/KNVLm),
with an English proficiency rate of 70 percent, which highlights how important
specialized knowledge of the culture is for a marketer. Most Chinese-Americans
can be found in California, with 604,000 in Los Angeles, 519,000 in San
Francisco and 194,000 in San Jose, but New York also has a substantial number
(798,000 in NYC).
Chinese-Americans are also open to using nutraceuticals
because of their exposure and familiarity with traditional Chinese medicine
(TCM), which embraces herbal remedies. Moreover, TCM and nutraceuticals are
receiving official support. No less a personage than China’s president, Xi
Jinping, has been promoting TCM, calling it “the gem of Chinese traditional
science.” He is urging practitioners to “push for TCM to step onto the world
stage”, according to the Economist (http://ibn.fm/NG5IN). As a result, around 60,000 TCM
treatment options have been approved by the government’s food and drug
regulator, accounting for almost a third of China’s pharmaceutical market, the
world’s second-largest.
The Chinese public has been welcomingly receptive. The
number of patients visiting TCM hospitals and doctors has risen. In 2011, they
accounted for 14 percent of health care; by 2015, they comprised 16 percent. It
seems very likely that the CBD products being marketed by Cannabis Strategic
Ventures will align with these cultural and historical trends.
For more information, visit the company’s website at www.CannabisStrategic.com
About MissionIR
MissionIR is
primarily focused on strategic communications. We have executed countless
communications programs to address the needs of companies ranging from
start-ups to established industry leaders, gaining valuable experience and the
expertise necessary to determine the most effective strategy for any given
situation.
For more information, visit www.MissionIR.com
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
